Equations and Enzymes Flashcards

1
Q
  • made up of many different enzymes
  • enzymes can be inhibited or induced
  • genetic variations can alter activity
  • Part of Liver Metabolism: Phase I Enzymes
A

P - 450 System

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  • METABOLIZES 50% of MEDICATIONS
  • basis for many drug interactions
  • Most important enzyme of P-450 system
A

CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What type of metabolism occurs when a prodrug becomes an active compound?

A

Inactive Drug to Active Metabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What type of metabolism occurs when a metabolite is further metabolized?
(Heroin –> Morphine)

A

Active Drug to Active Metabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What type of metabolism occurs when the drug is ready for excretion and is the most common form of drug deactivation?

A

Active Drug to Inactive Metabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What type of metabolism occurs when a metabolite is then further metabolized into a toxic metabolite?
(one of the metabolites of acetaminophen is toxic)

A

Active Drug to Toxic Metabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Volume of Distribution (Vd) Equation

A

Vd = (Dose) / (plasma concentration)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Bioavailability Equation

A

AUCₒᵣₐₗ / AUCᵢᵥ = f

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Amount of drug that is absorbed after oral administration vs. the amount of drug that is absorbed after IV administration

A

Bioavailability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bioavailability of drugs given IV

A

f = 1 (100%) because they do not undergo first pass.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Rate at which a drug is cleared from the body

A

Clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Clearance Equation

A

Clearance = (Rate of Drug Elimination) / (Plasma Concentration)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

A CONSTANT % of the DRUG IS LOST PER UNIT of TIME
90% OF DRUGS FOLLOW THIS

A

First-Order Kinetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Time it takes for the blood level (concentration) of a drug to fall exactly half (50%)

A

Half-life
increased concentration = increased half life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Point where drug accumulation equals drug elimination

A

Steady State Concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How many half lives are needed to reach Steady State Concentration?

A

5 Half-lives

17
Q

Single large dose of a drug used to raise the plasma concentration to a therapeutic level more quickly than would occur through repeated smaller doses

A

Loading Dose

18
Q

CONSTANT AMOUNT OF DRUG IS LOST PER UNIT OF TIME

A

Zero-Order Kinetics

19
Q

Up to 25% of all drugs are metabolized via this enzyme.
- Beta Blockers
- Opioids
- Antipsychotics

A

CYP2D6

20
Q

Preference for acidic drugs
- PPI
- Antidepressants
- Antiplatelets
- Polymorphism in Asian populations

A

CYP2C19

21
Q

Clinical significance in cancer and immunological treatments
- UGT1A1 & TMPT

A

Phase II Enzymes

22
Q
  • Rate limiting step in Pentos Phosphate Pathway
  • Significant source of NADPH in body
  • African and Mediterranean Populations
    Leads to Hemolysis
A

G6PD

23
Q

Drug Induced Hypersensitivity Reaction

A

Rash due to severe skin toxicity
- Steven Johnson Syndrome (SJS)
- Toxic Epidermal Necrosis (TEN)

24
Q

Genetic component determines if sustained virology response of anti-viral medication is likely
- European populations

A

IFNL3

25
Q

Indication: HIV
Tested: All patients
Test: HLA-B*5701 gene
Result: if (+) do NOT use
Clinical: ↑risk of serious hypersensitivity reactions
- beware of combination products that contain the drug

A

Abacavir (Ziagen)

26
Q

Indication: Epilepsy, neuralgias, BPD
Tested: Asian patients
Test: HLA-B*1502 gene
Result: if (+) do NOT use
Clinical: ↑risk of SJS and TEN

A

Carbamazepine (Tegretol)

27
Q

Indication: HIV
Tested: All patients
Test: HIV Tropism with Trofile
Result: Must be CCR5 (+) to use
Clinical: Patients with only CCR5 can use this drug

A

Maraviroc (Selzentry)

28
Q

Indication: Gout
Tested: Chinese, Thai, or Korean with Renal impairment
Test: HLA-B*5801 gene
Result: If (+) not recommended
Clinical: ↑Risk of serous dermatologic reaction
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome

A

Allopurinol

29
Q

Indication: Acute Coronary Syndrome
Tested: Patients at initial treatment
Test: CYP2C19 gene
Poor Metabolizers = 2C19*2 or 3
Fully Functional = 2C19
1
Clinical: ↑risk of cardiovascular events

A

Clopidogrel (Plavix)

30
Q

Indication: Pain or Cough
Tested: Not typically tested
Test: CYP2D6 gene
Ultra-rapid metabolizers = 2D6*2 allele
Clinical: ↑Respiratory depression

A

Codeine

31
Q

Clot prevention & treatment
Tested: Not typically tested
Test: CYP2C9 and VKORC1 gene
2C92 or 2C93 or VKORC1 G = USE LOWER STARTING DOSE
Clinical: ↑Risk of bleeding due to decreased metabolism

A

Warfarin (Coumadin)

32
Q

Clinical testing is carried out in human volunteers in three formal phases of clinical trials
- Institutional Review Board must approve the study
- Volunteers are informed of possible risks
- Chronic safety testing in animals goes on concurrently

A

Clinical Trials

33
Q

20-100 healthy volunteers
(do not target disease)
Evaluates safety
Determines dosage range
Identifies adverse effects or toxicities

A

Phase 1

34
Q

Studies 100-300 patients
(with target disease)
Determines efficacy and dose
Evaluates short-term effects and risks
Only 25% of drugs make it here

A

Phase 2

35
Q

Tested in formulation for market
Establishes and confirms safety and efficacy
2-10 years
If good results –> application to FDA
- Review may take months to years

A

Phase 3

36
Q

Important phase that relies on you as a provider
Drug has been approved to market
Adverse effects reported to FDA through MedWatch program

A

Phase 4